Consolidation for ovarian cancer in remission.
Sabbatini
Paul
P
Spriggs
David R
DR
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000187:drug effects / Q000302:isolation & purification; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008565:Membrane Proteins; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000601:surgery*; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes
D000911:Antibodies, Monoclonal; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins; D015021:Yttrium Radioisotopes; C469215:pemtumomab